ERBB2 and cancer: It was assessed that HER-2 overexpression through the activation of PI3K/Akt and upregulation of survivin allows cancer cells to escape from cytotoxic effects, e.g., Dtx through early mitotic exit and by activating the multi-drug efflux pump [149].